NASDAQ:SABS

SAB Biotherapeutics (SABS) Stock Price, News & Analysis

SAB Biotherapeutics logo
$2.81 -0.10 (-3.44%)
Closing price 04:00 PM Eastern
Extended Trading
$2.81 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About SAB Biotherapeutics Stock (NASDAQ:SABS)

Advanced

Key Stats

Today's Range
$2.64
▼
$2.89
50-Day Range
$2.49
▼
$3.51
52-Week Range
$2.44
▼
$5.15
Volume
874,026 shs
Average Volume
651,139 shs
Market Capitalization
$253.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Moderate Buy

Company Overview

SAB Biotherapeutics is a biotechnology company developing antibody-based medicines for autoimmune and infectious diseases. Its platform uses genetically engineered cattle to produce fully human polyclonal antibodies, which the company evaluates as potential treatments.

The company’s pipeline has included SAB-142, an investigational therapy being developed for type 1 diabetes. Earlier programs included antibody candidates targeting infectious diseases, such as influenza and COVID-19.

SAB Biotherapeutics was founded in 2014 and is based in Sioux Falls, South Dakota. Its work focuses on research and development; the company’s products are investigational and are not established treatments.

AI Generated. May Contain Errors.

SAB Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

SABS MarketRank™: 
1.911382002465 of 5 stars

SAB Biotherapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 701st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SAB Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    SAB Biotherapeutics has a consensus price target of $12.00, representing about 323.9% upside from its current price of $2.83.

  • Amount of Analyst Coverage

    SAB Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about SAB Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for SAB Biotherapeutics are expected to grow in the coming year, from ($1.13) to ($0.87) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SAB Biotherapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SAB Biotherapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SAB Biotherapeutics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.96% of the float of SAB Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    SAB Biotherapeutics has a short interest ratio ("days to cover") of 8.28.
  • Change versus previous month

    Short interest in SAB Biotherapeutics has recently increased by 4.66%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    SAB Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    SAB Biotherapeutics does not have a long track record of dividend growth.

  • News Sentiment

    SAB Biotherapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for SAB Biotherapeutics this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    5 people have added SAB Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    7.39% of the stock of SAB Biotherapeutics is held by insiders.

  • Percentage Held by Institutions

    7.82% of the stock of SAB Biotherapeutics is held by institutions.

  • Read more about SAB Biotherapeutics' insider trading history.
Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SABS Stock News Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
FY2026 EPS Estimate for SAB Biotherapeutics Cut by Analyst
SAB Biotherapeutics (SABS) Gets a Buy from Guggenheim
See More Headlines

SABS Stock Analysis - Frequently Asked Questions

SAB Biotherapeutics' stock was trading at $3.74 at the beginning of the year. Since then, SABS stock has decreased by 24.3% and is now trading at $2.8310.

SAB Biotherapeutics, Inc. (NASDAQ:SABS) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.03.
Read the conference call transcript
.

SAB Biotherapeutics' top institutional investors include State Street Corp (0.82%), Soleus Capital Management L.P. (0.75%), Goldman Sachs Group Inc. (0.22%) and Alps Advisors Inc. (0.13%). Insiders that own company stock include Eddie Joe Sullivan and Michael King.
View institutional ownership trends
.

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SAB Biotherapeutics investors own include NVIDIA (NVDA), IonQ (IONQ), Palantir Technologies (PLTR), Ford Motor (F), Black Diamond Therapeutics (BDTX), Bit Digital (BTBT) and Cabaletta Bio (CABA).

Company Calendar

Last Earnings
11/05/2026
Today
11/20/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SABS
CIK
1833214
Fax
N/A
Employees
86
Year Founded
2014

Price Target and Rating

High Price Target
$16.00
Low Price Target
$7.00
Potential Upside/Downside
+323.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.33)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$13.27 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-40.04%
Return on Assets
-35.98%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
7.28
Quick Ratio
7.28

Sales & Book Value

Annual Sales
$1.32 million
Price / Sales
193.49
Cash Flow
$0.30 per share
Price / Cash Flow
9.37
Book Value
$2.34 per share
Price / Book
1.21

Miscellaneous

Outstanding Shares
90,090,000
Free Float
83,431,000
Market Cap
$255.41 million
Optionable
Optionable
Beta
0.67

Social Links

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

This page (NASDAQ:SABS) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners